$NXGL

Levy Adam R. sold $1K of NXGL

Levy Adam R. (Chief Executive Officer) sold 2,000 shares of NEXGEL, INC. (NXGL) at $0.59 on 2026-06-01.

Original reporting
SEC EDGAR · Levy Adam R.
Published Jun 3, 2026, 10:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 10:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NXGL
Bearish
medium confidence
Mentioned
$NXGL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NXGLBearishLow
01

Why it matters

Traders may treat it as a mild sentiment datapoint, but without accompanying fundamental news it is unlikely to drive a sustained repricing.

02

Market read

NXGL receives attention due to CEO selling disclosed on June 3 for a June 1 open-market sale.

03

What to watch

No 10b5-1 plan is cited; however, Form 4s alone rarely clarify intent, and the filing does not include follow-on guidance or operational changes.

Relevance 6/10Novelty 6/10Timing: Disclosure filed June 3, covering a June 1 sale.

Background

This is an SEC Form 4 insider transaction: CEO/director sold shares in an open-market sale; no pre-arranged 10b5-1 plan is indicated.

Company-level read

Ticker impact

$NXGLBearishMedium confidence
Context

CEO Levy Adam R. sold 2,000 shares in an open-market transaction disclosed via SEC Form 4 on June 1, 2026.

Expected impact

Likely small, short-lived drift or noise around the disclosure; no strong directional move expected from this single sale.

Evidence & confidence

The filing is an ownership-change disclosure (not earnings/M&A/regulatory/drug data). It does not indicate a new catalyst; insider sales can be routine and are not necessarily predictive.

Market effects

Minimal; insider Form 4s typically do not reset sector expectations.

None indicated.

None indicated.

Counterpoint

The sale may be non-informational (liquidity/tax/portfolio rebalancing), especially since it is a small value relative to typical company market caps.

Key entities

  • NEXGEL, INC.

    Subject of the insider transaction disclosure (NXGL).

  • Levy Adam R.

    Chief Executive Officer and director who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NXGLLow

NEXGEL, INC. (NXGL): Results of Operations and Financial Condition

NEXGEL, INC. (NXGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEXGEL Reports Second Quarter 2026 Financial Results LANGHORNE, Pa. – August 17, 2026 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content